Date | Open | Close | Daily High | Daily Low |
---|
Date | Analyst | Rating | Price | |||
---|---|---|---|---|---|---|
07/11/25 | Mizuho | Maintained Buy | $330 | gut | ||
07/10/25 | Morgan Stanley | Downgraded to Hold | $266 | neutral | ||
06/09/25 | Barclays Capital | Maintained Hold | $347 | neutral | ||
06/09/25 | Morgan Stanley | Maintained Buy | $364 | gut | ||
06/02/25 | Barclays Capital | Maintained Hold | $351 | neutral | ||
04/25/25 | Barclays Capital | Maintained Hold | $362 | neutral | ||
04/22/25 | Bernstein | Maintained Buy | $414 | gut | ||
04/15/25 | Baird Patrick & Co | Downgraded to Hold | $375 | neutral | ||
04/09/25 | Guggenheim | Maintained Hold | neutral | |||
04/09/25 | Mizuho | Maintained Buy | $400 | gut | ||
03/05/25 | Wells Fargo & Co | Upgraded to Buy | $372 | gut | ||
03/03/25 | Mizuho | Maintained Buy | $376 | gut | ||
02/07/25 | Barclays Capital | Maintained Hold | $339 | neutral | ||
02/07/25 | UBS | Maintained Hold | $325 | neutral | ||
02/06/25 | Stephens Inc. | Maintained Hold | $345 | neutral | ||
07/29/24 | Deutsche Bank | Maintained Hold | $353 | neutral | ||
07/25/24 | Stephens Inc. | Maintained Hold | $320 | neutral | ||
07/24/24 | Jefferies & Company Inc. | Maintained Hold | $297 | neutral | ||
07/23/24 | Cantor Fitzgerald | Maintained Buy | $406 | gut | ||
07/22/24 | Wells Fargo & Co | Maintained Hold | $315 | neutral | ||
07/10/24 | J.P. Morgan | Maintained Buy | $395 | gut | ||
05/30/24 | J.P. Morgan | Maintained Buy | $420 | gut | ||
05/30/24 | Baird Patrick & Co | Maintained Buy | $405 | gut | ||
04/29/24 | Wells Fargo & Co | Maintained Hold | $375 | neutral | ||
04/25/24 | Barclays Capital | Maintained Hold | $430 | neutral | ||
04/25/24 | Stephens Inc. | Maintained Hold | $390 | neutral | ||
04/15/24 | Wells Fargo & Co | Maintained Hold | $410 | neutral | ||
04/04/24 | Cantor Fitzgerald | Maintained Buy | $406 | gut | ||
04/01/24 | Bank of America Merrill Lynch | Downgraded to Sell | $439 | schlecht | ||
03/28/24 | Bank of America Merrill Lynch | Downgraded to Sell | $439 | schlecht | ||
03/20/24 | Wells Fargo & Co | Maintained Hold | $440 | neutral | ||
03/06/24 | Barclays Capital | Maintained Hold | $437 | neutral | ||
02/15/24 | Wells Fargo & Co | Upgraded to Hold | $420 | neutral | ||
02/09/24 | Cantor Fitzgerald | Maintained Buy | $406 | gut | ||
12/21/23 | UBS | Maintained Hold | $380 | neutral | ||
11/21/23 | Cantor Fitzgerald | Maintained Buy | $374 | gut | ||
11/17/23 | J.P. Morgan | Maintained Buy | $392 | gut | ||
10/03/23 | Stephens Inc. | Maintained Hold | $350 | neutral | ||
09/14/23 | Cantor Fitzgerald | Maintained Buy | $359 | gut |
2025 | 2026 | 2027 | 2028 | 2029 | |
---|---|---|---|---|---|
Revenue | 44,208 | 47,531 | 49,790 | 52,290 | 52,169 |
Dividend | 0.00 | 0.00 | 0.00 | - | - |
Dividend Yield (in %) | 0.00 % | 0.00 % | 0.00 % | - | - |
EPS | 22.59 | 26.18 | 29.28 | 36.14 | 38.57 |
P/E Ratio | 8.10 | 6.99 | 6.25 | 5.06 | 4.74 |
EBIT | - | - | - | 2,730 | 2,510 |
EBITDA | 1,950 | 2,201 | 2,203 | - | - |
Net Profit | 1,259 | 1,428 | 1,566 | 1,904 | 1,784 |
Net Profit Adjusted | 1,259 | 1,428 | 1,566 | 1,904 | 1,784 |
Pre-Tax Profit | 1,623 | 1,865 | 2,081 | 2,518 | 2,314 |
Pre-Tax Profit Reported | - | - | - | 2,565 | 2,781 |
EPS (Non-GAAP) ex. SOE | 22.14 | 25.67 | 28.36 | - | - |
EPS (GAAP) | 21.42 | 24.87 | 28.07 | 32.87 | 36.90 |
Gross Income | 6,501 | 6,979 | 7,547 | - | - |
Cash Flow from Investing | -332 | -304 | -97 | - | - |
Cash Flow from Operations | 914 | 1,665 | 1,847 | - | - |
Cash Flow from Financing | -376 | -162 | -443 | - | - |
Cash Flow per Share | - | - | - | - | - |
Free Cash Flow | 1,199 | 1,668 | 1,573 | 1,878 | 2,029 |
Free Cash Flow per Share | - | - | - | - | - |
Book Value per Share | 99.88 | 130.70 | 172.42 | - | - |
Net Debt | -3,255 | -4,947 | -7,104 | - | - |
Research & Development Exp. | - | - | - | - | - |
Capital Expenditure | 136 | 105 | 113 | 98 | 103 |
Selling, General & Admin. Exp. | 3,437 | 3,718 | 3,331 | - | - |
Shareholder’s Equity | 4,962 | 6,242 | 6,850 | - | - |
Total Assets | 16,373 | 18,033 | 18,639 | - | - |
Previous Quarter ending 06/30/25 |
Current Quarter ending 09/30/25 |
Next Quarter ending 12/31/25 |
Current Year ending 12/31/25 |
Next Year ending 12/31/26 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | 17 | 17 | 17 | 17 | 17 |
Average Estimate | 5.701 USD | 5.778 USD | 5.234 USD | 22.594 USD | 26.183 USD |
Year Ago | 5.181 USD | 5.660 USD | 4.482 USD | 20.540 USD | - |
Publish Date | 7/23/2025 | 10/22/2025 | 2/11/2026 | - | - |
Revenue Estimates | |||||
No. of Analysts | 12 | 12 | 12 | 15 | 14 |
Average Estimate | 10,952 USD | 10,971 USD | 11,129 USD | 44,208 USD | 47,531 USD |
Year Ago | 9,859 USD | 10,340 USD | 10,499 USD | 40,650 USD | - |
Publish Date | 7/23/2025 | 10/22/2025 | 2/11/2026 | - | - |
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|---|
Sales | 40,650.00 | 34,072.00 | 31,974.00 | 27,771.00 | 19,295.00 | 16,829.00 | 18,890.00 |
Change of sales in % | 19.31 | 6.56 | 15.13 | 43.93 | 14.65 | -10.91 | -4.99 |
Gross profit on sales | - | - | - | - | - | - | - |
Gross profit on sales change in % | - | - | - | - | - | - | - |
Operating income | 1,707.00 | 1,573.00 | 1,381.00 | 1,020.00 | 950.00 | 1,050.00 | 1,192.00 |
Operating income change in % | 8.52 | 13.90 | 35.39 | 7.37 | -9.52 | -11.91 | 700.00 |
Income before tax | 1,589.00 | 1,464.00 | 1,063.00 | 875.00 | 961.00 | 972.00 | 999.00 |
Income before tax change in % | 8.54 | 37.72 | 21.49 | -8.95 | -1.13 | -2.70 | - |
Income after tax | 1,179.00 | 1,091.00 | 792.00 | 659.00 | 673.00 | 737.00 | 707.00 |
Income after tax change in % | 8.07 | 37.75 | 20.18 | -2.08 | -8.68 | 4.24 | - |
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|---|
Total liabilities | 11,186.00 | 10,720.00 | 9,365.00 | 9,593.00 | 7,465.00 | 4,836.00 | 5,513.00 |
Long-term liabilities per share | - | - | - | - | - | - | - |
Equity | 4,496.00 | 4,215.00 | 2,964.00 | 2,630.00 | 2,096.00 | 1,960.00 | 1,647.00 |
Equity change in % | 6.67 | 42.21 | 12.70 | 25.48 | 6.94 | 19.00 | 23.19 |
Balance sheet total | 15,682.00 | 14,935.00 | 12,329.00 | 12,223.00 | 9,561.00 | 6,796.00 | 7,160.00 |
Balance sheet total change in % | 5.00 | 21.14 | 0.87 | 27.84 | 40.69 | -5.08 | -15.63 |
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|---|---|
Sales per share | 704.51 | 586.44 | 546.56 | 473.91 | 322.12 | 262.13 | 281.94 |
P/E ratio (year end quote, basic EPS) | 14.24 | 19.24 | 24.39 | 28.28 | 18.93 | 11.82 | 11.01 |
P/E ratio (year end quote, diluted EPS) | 14.24 | 19.24 | 24.39 | 28.28 | 18.93 | 11.82 | 11.01 |
Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Equity ratio in % | 28.67 | 28.22 | 24.04 | 21.52 | 21.92 | 28.84 | 23.00 |
Debt ratio in % | 71.33 | 71.78 | 75.96 | 78.48 | 78.08 | 71.16 | 77.00 |
Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
---|---|---|---|---|---|---|
Bacon Debra | 06/30/2025 | 183.00 | 12,884.00 | 306.29 | Sell | No |
ORLANDO STEVEN J | 06/30/2025 | 180.00 | 16,723.00 | 306.29 | Buy | No |
Schapiro Richard M | 06/30/2025 | 180.00 | 11,424.00 | 306.29 | Buy | No |
WOLF DALE B | 06/30/2025 | 180.00 | 14,389.00 | 306.29 | Buy | No |
Barlow Jeff D. | 06/29/2025 | 85.00 | 72,902.00 | 247.39 | Buy | No |
Bacon Debra | 06/29/2025 | 41.00 | 13,067.00 | 247.39 | Buy | No |
WOLF DALE B | 05/20/2025 | 100.00 | 15,609.00 | 320.51 | Sell | No |
WOLF DALE B | 05/20/2025 | 900.00 | 14,309.00 | 323.27 | Sell | No |
WOLF DALE B | 05/20/2025 | 100.00 | 14,209.00 | 324.42 | Sell | No |
WOLF DALE B | 05/20/2025 | 400.00 | 15,209.00 | 322.23 | Sell | No |
GROHOWSKI LEO P | 04/30/2025 | 118.00 | 118.00 | 313.04 | Buy | No |
Zubretsky Joseph M | 04/29/2025 | 86,400.00 | 258,815.00 | 320.00 | Sell | No |
Zubretsky Joseph M | 04/29/2025 | 1,100.00 | 257,715.00 | 324.70 | Sell | No |
Schapiro Richard M | 04/28/2025 | 669.00 | 11,244.00 | 320.50 | Sell | No |
Lockhart Stephen H | 03/31/2025 | 168.00 | 2,960.00 | 327.71 | Buy | No |
ORLANDO STEVEN J | 03/31/2025 | 168.00 | 17,543.00 | 327.71 | Buy | No |
Schapiro Richard M | 03/31/2025 | 168.00 | 11,913.00 | 327.71 | Buy | No |
ROMNEY RONNA | 03/31/2025 | 168.00 | 17,651.00 | 327.71 | Buy | No |
ZORETIC RICHARD C | 03/31/2025 | 168.00 | 7,165.00 | 327.71 | Buy | No |
WOLF DALE B | 03/31/2025 | 168.00 | 15,709.00 | 327.71 | Buy | No |
BRASIER BARBARA L | 03/31/2025 | 168.00 | 4,394.00 | 327.71 | Buy | No |
COOPERMAN DANIEL | 03/31/2025 | 56.00 | 6,383.00 | 327.71 | Buy | No |
ORLANDO STEVEN J | 03/02/2025 | 1,000.00 | 17,375.00 | 301.33 | Sell | No |
Barlow Jeff D. | 02/28/2025 | 1,851.00 | 67,958.00 | 301.12 | Sell | No |
WOYS JAMES | 02/28/2025 | 1,599.00 | 57,998.00 | 301.12 | Sell | No |
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2024 | Molina Healthcare | 0.00 | 0.00 | USD |
2023 | Molina Healthcare | 0.00 | 0.00 | USD |
2022 | Molina Healthcare | 0.00 | 0.00 | USD |
2021 | Molina Healthcare | 0.00 | 0.00 | USD |
2020 | Molina Healthcare | 0.00 | 0.00 | USD |
2019 | Molina Healthcare | 0.00 | 0.00 | USD |
2018 | Molina Healthcare | 0.00 | 0.00 | USD |
2017 | Molina Healthcare | 0.00 | 0.00 | USD |
2016 | Molina Healthcare | 0.00 | 0.00 | USD |
2015 | Molina Healthcare | 0.00 | 0.00 | USD |
2014 | Molina Healthcare | 0.00 | 0.00 | USD |
2013 | Molina Healthcare | 0.00 | 0.00 | USD |
2012 | Molina Healthcare | 0.00 | 0.00 | USD |
2011 | Molina Healthcare | 0.00 | 0.00 | USD |
2010 | Molina Healthcare | 0.00 | 0.00 | USD |
2009 | Molina Healthcare | 0.00 | 0.00 | USD |
2008 | Molina Healthcare | 0.00 | 0.00 | USD |
Event | Estimate | Info | Date |
---|---|---|---|
Earnings Report | 5.701 USD | Q2 2025 Earnings Release | 07/23/2025 |
Earnings Report | 5.778 USD | Q3 2025 Earnings Release | 10/22/2025 |
Earnings Report | 5.234 USD | Q4 2025 Earnings Release | 02/11/2026 |
Earnings Report | 6.779 USD | Q1 2026 Earnings Release | 04/29/2026 |
Earnings Report | 6.621 USD | Q2 2026 Earnings Release | 07/29/2026 |
Event | Actual EPS | Info | Date |
---|---|---|---|
Annual General Meeting | 20.420 USD | Annual General Meeting | 04/30/2025 |
Earnings Report | 5.450 USD | Q1 2025 Earnings Release | 04/23/2025 |
Earnings Report | 4.440 USD | Q4 2024 Earnings Release | 02/05/2025 |
Earnings Report | 5.650 USD | Q3 2024 Earnings Release | 10/23/2024 |
Earnings Report | 5.170 USD | Q2 2024 Earnings Release | 07/24/2024 |
Annual General Meeting | 18.770 USD | Annual General Meeting | 05/01/2024 |
Earnings Report | 5.170 USD | Q1 2024 Earnings Release | 04/24/2024 |
Earnings Report | 3.700 USD | Q4 2023 Earnings Release | 02/07/2024 |
Earnings Report | 4.210 USD | Q3 2023 Earnings Release | 10/25/2023 |
Earnings Report | 5.350 USD | Q2 2023 Earnings Release | 07/26/2023 |
Annual General Meeting | 13.550 USD | Annual General Meeting | 05/03/2023 |
Earnings Report | 5.520 USD | Q1 2023 Earnings Release | 04/26/2023 |
Earnings Report | 0.960 USD | Q4 2022 Earnings Release | 02/08/2023 |
Earnings Report | 3.950 USD | Q3 2022 Earnings Release | 10/26/2022 |
Earnings Report | 4.250 USD | Q2 2022 Earnings Release | 07/27/2022 |
Annual General Meeting | 11.250 USD | Annual General Meeting | 05/04/2022 |
Earnings Report | 4.390 USD | Q1 2022 Earnings Release | 04/27/2022 |
Earnings Report | 1.740 USD | Q4 2021 Earnings Release | 02/09/2022 |
Name | Job |
---|---|
Maurice S. Hebert | Chief Accounting Officer |
Mark L. Keim | Chief Financial Officer & Senior Executive VP |
Lawrence D. Anderson | Chief Human Resources Officer |
Amir Desai | Chief Information Officer |
Carolyn Ingram | Chief Marketing Officer |
Jason Dees | Chief Medical Officer |
James E. Woys | Chief Operating Officer |
Ronald M. Kurtz | Chief of Staff |
Leo P. Grohowski | Director |
Debra J. Bacon | Executive Vice President-Medicaid |
Barbara L. Brasier | Independent Director |
Richard C. Zoretic | Independent Director |
Richard M. Schapiro | Independent Director |
Stephen H. Lockhart | Independent Director |
Steven J. Orlando | Independent Director |
Dale B. Wolf | Non-Executive Chairman |
Joseph M. Zubretsky | President, Chief Executive Officer & Director |
Jeff D. Barlow | Secretary & Chief Legal Officer |
Steve O'Dell | Senior VP-Growth & Corporate Development |
Ronna E. Romney | Vice Chairman |
Jeffrey Geyer | Vice President-Investor Relations |